EP
APLT

Essential Partners’s Applied Therapeutics APLT Stock Holding History

Essential Partners’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-225
Closed -$70 – 2676
2025
Q2 		$70 Buy
+225
New +$87 ﹤0.01% 2111

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Essential Partners's APLT Position: Q3 2025 in Review

Essential Partners sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 225 shares — an estimated $70 sold.

Essential Partners first reported a position in APLT in Q2 2025 and held it in 1 quarter. The position peaked at $70 in Q2 2025. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.

  • Essential Partners reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 225 Applied Therapeutics shares in Q3 2025, an estimated $70.
  • Essential Partners first reported a position in Applied Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Applied Therapeutics position peaked at $70 in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.